^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/09/2021
Excerpt:
Gastric cancer: Preferred regimens...fam-trastuzumab deruxtecan-nxki for HER2 overexpression positive adenocarcinoma
Source:
Title:
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
Excerpt:
...- Pathologically documented adenocarcinoma of the stomach (clinical stage before surgery of AJCC I-III), gastroesophageal junction, or lower oesophagus (to include Type I Siewert only), with HER2 overexpression (IHC 3+ or IHC 2+/ISH+) based on local tissue testing results....
Trial ID:
Source:
Title:
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Excerpt:
...- Advanced breast cancer with HER2 overexpression that is refractory to or intolerable with standard treatment, or for which...
Trial ID:
More C2 evidence
Source:
Title:
Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma
Excerpt:
...Has HER2 overexpression (IHC3+, or IHC2+ and ISH positive [FISH or DISH])....
Trial ID:
Source:
Title:
A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or in combination with other agents in patients with HER2- expressing Gastric Cancer
Excerpt:
...Disease Characteristics: Locally advanced, unresectable, or metastatic disease Pathologically documented adenocarcinoma of the stomach/GEJ/esophagus with HER2 overexpression (IHC 3+ or IHC 2+/ISH+)3. ...
Trial ID:
